Journal article
Is the Health Utilities Index 3 valid for patients with ankylosing spondylitis?
Abstract
OBJECTIVE: To assess the convergent and discriminative validity of the Health Utilities Index Mark 3 (HUI-3) for patients with ankylosing spondylitis (AS).
METHODS: Data were derived from the Adalimumab Trial evaluating Long-term efficacy and safety for Ankylosing Spondylitis (ATLAS). The study team specified 90 a priori hypotheses regarding the direction and magnitude of the expected associations between the overall and single-attribute scores …
Authors
Gooch K; Feeny D; Wong RL; Kupper H; Pangan AL; Revicki DA; van der Heijde D
Journal
Value in Health, Vol. 14, No. 1, pp. 160–165
Publisher
Elsevier
Publication Date
1 2011
DOI
10.1016/j.jval.2010.10.012
ISSN
1098-3015